文献类型：期刊文献

英文题名：Tisotumab vedotin for the treatment of cervical carcinoma

作者：Song, Xin[1,2];Li, Ruyi[3];Wang, Hongwei[1];Song, Peng[1];Guo, Wenjing[4];Chen, Zhe-Sheng[5]

第一作者：Song, Xin

通信作者：Song, P[1];Guo, WJ[2];Chen, ZS[3]

机构：[1]Gansu Univ Chinese Med, Key Lab Prevent & Treatment Chron Dis TCM Gansu P, Affiliated Hosp, 732 Jia Yuguan West Rd, Lanzhou 730000, Peoples R China;[2]Lanzhou Univ Technol, Sch Life Sci & Engn, Lanzhou, Peoples R China;[3]Zhengzhou Univ, Dept Resp & Crit Care Med, Affiliated Hosp 1, Zhengzhou, Peoples R China;[4]Gansu Univ Chinese Med, Res Ctr Tradit Chinese Med Gansu Prov, 35 Ding Xi East Rd, Lanzhou 730000, Peoples R China;[5]St Johns Univ, Dept Pharmaceut Sci, Coll Pharm & Hlth Sci, New York, NY 11439 USA

第一机构：甘肃中医药大学第二附属医院

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Key Lab Prevent & Treatment Chron Dis TCM Gansu P, Affiliated Hosp, 732 Jia Yuguan West Rd, Lanzhou 730000, Peoples R China;[2]corresponding author), Gansu Univ Chinese Med, Res Ctr Tradit Chinese Med Gansu Prov, 35 Ding Xi East Rd, Lanzhou 730000, Peoples R China;[3]corresponding author), St Johns Univ, Dept Pharmaceut Sci, Coll Pharm & Hlth Sci, New York, NY 11439 USA.|[10735]甘肃中医药大学;[10735b845793de6ae2b30]甘肃中医药大学第二附属医院;

年份：2022

卷号：58

期号：5

起止页码：213

外文期刊名：DRUGS OF TODAY

收录：;WOS:【SCI-EXPANDED(收录号:WOS:000798014300001)】；

基金：This work was supported by the National Natural Science Foundation of China (81803779); the Gansu Province Science Foundation for Distinguished Young Scholars (20JR10RA348) and the Gansu Province Science Foundation for B Program (1508RJZA018) from Gansu Provincial Sci. & Tech. Department; the Open Project of Research Center of Traditional Chinese Medicine, Gansu Province (zyzx-2020-zx1); and the Innovation Fund Project of Affiliated Hospital of Gansu University of Chinese Medicine (gzfy-2020-8).

语种：英文

外文关键词：Tisotumab vedotin; Antibody-drug conjugates; Cervical cancer; Tissue factor; Monomethyl auristatin E; Targeted antitumor drugs; Cancer immunotherapy; Gynecological cancers

摘要：Cervical cancer is one of the most common gynecological malignancies. At present, cytotoxic chemotherapeutic drugs and immunotherapy are the main therapeutic options for recurrent and metastatic cervical cancer. Tisotumab vedotin is an antibody-drug conjugate (ADC) and a potential novel treatment for cervical carcinoma. Tisotumab vedotin targets tissue factor (TF), which is highly expressed on the surface of cervical cancer cells, by delivering the cytotoxic agent monomethyl auristatin E (MMAE) directly into tumor cells. Currently, the U.S. Food and Drug Administration (FDA) has approved tisotumab vedotin for the treatment of adult female patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This article reviews the results of preclinical studies and clinical trials of tisotumab vedotin. The findings suggest that tisotumab vedotin can induce clinically significant and long-lasting remission with controllable and tolerable safety in the difficult-to-treat group of cervical cancer patients.